Halozyme Announces argenx Receives FDA Approval for Vyvgart® Hytrulo Co-Formulated With Enhanze® for Chronic Inflammatory Demyelinating Polyneuropathy
Halozyme宣佈argenx獲得FDA批准,使用Enhanze®與Vyvgart®聯合制劑治療慢性炎症性脫髓鞘多發性神經病。
Halozyme Announces argenx Receives FDA Approval for Vyvgart® Hytrulo Co-Formulated With Enhanze® for Chronic Inflammatory Demyelinating Polyneuropathy
Halozyme宣佈argenx獲得FDA批准,使用Enhanze®與Vyvgart®聯合制劑治療慢性炎症性脫髓鞘多發性神經病。
譯文內容由第三人軟體翻譯。